{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:54:38Z","timestamp":1790646878003,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The role of conversion surgery in patients with unresectable biliary tract cancer who responded positively to PD-1\/PD-L1 inhibitor-based therapy remains unclear. This study aimed to assess the outcomes in patients with or without conversion surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this cohort study, patients with advanced biliary tract cancer who received combination therapy with PD-1\/PD-L1 inhibitors from July 2019 to January 2023 were retrospectively. Patients who exhibited positive responses and met the criteria for conversion surgery were enrolled, and their surgical and oncological outcomes were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Out of 475 patients, 34 who met the conversion resection criteria were enrolled. The median follow-up was 40.5 months postinitiation of systemic therapy. Ultimately, 13 patients underwent conversion surgery, while 21 received continuation of systemic treatment alone (nonsurgical group). The median interval from the initial antitumor therapy to surgery was 6.7 [interquartile range (IQR) 4.9\u20139.2] months. Survival with conversion surgery was \ufeffsignificantly longer than the nonsurgical cohort, with a median progression-free survival (PFS) [unreached vs. 12.4 months; hazard ratio 0.17 (95% CI: 0.06\u20130.48); <jats:italic toggle=\"yes\">P<\/jats:italic>=0.001] and overall survival (OS) [unreached vs. 22.4 months; hazard ratio 0.28 (95% CI: 0.09\u20130.84); <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02], respectively. \ufeffAfter a median postoperative follow-up of 32.2 months in the surgical cohort, eight patients survived without recurrence. The estimated 3-year OS, PFS, and recurrence-free survival rate in the surgical cohort were 59.9, 59.2, and 60.6%, respectively. The R0 resection rate reached 92.3%, with two achieving a pathological complete response. One patient experienced a Clavien\u2013Dindo grade 3 complication without surgery-related mortality. No serious adverse events or surgical delays were observed. Multivariate analysis indicated that conversion surgery was independently associated with OS (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03) and PFS survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.003).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Conversion surgery appears safe and offers survival benefits to patients responding to immune checkpoint inhibitors-based combinations. However, further studies are required to validate this strategy in the era of immunotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000001540","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T18:01:12Z","timestamp":1714759272000},"page":"4608-4616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study"],"prefix":"10.1097","volume":"110","author":[{"given":"Shanshan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"},{"name":"Organ Transplantation Center, The First Affiliated Hospital of Shandong First Medical University, Jinan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"},{"name":"Department of General Surgery Center, Beijing Youan Hospital, Clinical Center for Liver Cancer, Capital Medical University, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"},{"name":"Department of General Surgery, Digestive Disease Hospital Affiliated to Zunyi Medical University, Affiliated Hospital of Zunyi Medical University Zunyi, Guizhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Sang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1097\/JS9.0000000000000738","article-title":"Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer","volume":"109","author":"Liang","year":"2023","journal-title":"Int J Surg"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann Surg"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"107694","DOI":"10.1016\/j.ijscr.2022.107694","article-title":"Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: case report and review of literature","volume":"100","author":"Al Jaber","year":"2022","journal-title":"Int J Surg Case Rep"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2016.12.058","article-title":"Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes","volume":"224","author":"Creasy","year":"2017","journal-title":"J Am Coll Surg"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","article-title":"Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study","volume":"20","author":"Kato","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"R11-20250824","doi-asserted-by":"crossref","first-page":"S1093","DOI":"10.1245\/s10434-015-4768-9","article-title":"Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery","volume":"22","author":"Kato","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R12-20250824","first-page":"1026","article-title":"Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-022-01307-2","article-title":"Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors","volume":"15","author":"Xu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"751391","DOI":"10.3389\/fonc.2021.751391","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00262-021-03121-0","article-title":"A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer","volume":"71","author":"Zuo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/j.annonc.2022.07.093","article-title":"65P A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers","volume":"33","author":"Li","year":"2022","journal-title":"Ann Oncol"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-022-00592-3","article-title":"Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma","volume":"19","author":"Ingels","year":"2022","journal-title":"Nat Rev Urol"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","article-title":"The combination of radiation therapy and immunotherapy is effective and well-tolerated for unresectable biliary tract cancer","volume":"113","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"907055","DOI":"10.3389\/fonc.2022.907055","article-title":"Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-a multi-center observational study","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00595-020-02031-5","article-title":"Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study","volume":"50","author":"Noji","year":"2020","journal-title":"Surg Today"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13691-022-00545-y","article-title":"Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review","volume":"11","author":"Miyamoto","year":"2022","journal-title":"Int Cancer Conf J"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40792-022-01406-9","article-title":"Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report","volume":"8","author":"Wakasa","year":"2022","journal-title":"Surg Case Rep"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41585-023-00776-5","article-title":"Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC","volume":"20","author":"Das","year":"2023","journal-title":"Nat Rev Urol"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"977963","DOI":"10.3389\/fonc.2022.977963","article-title":"Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:22:34Z","timestamp":1756063354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001540","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2024-02-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}